Outcomes in Pump- and CGM-Baseline Use Subgroups in the International Diabetes Closed-Loop Trial
Authors' conclusion
There was a consistent benefit in patients with T1D when using CLC, regardless of baseline insulin delivery modality or CGM use. These data suggest that this CLC system can be considered across a wide range of patients.
Study context
- Population
- Individuals with T1D, stratified by baseline device use: pump+continuous glucose monitor (CGM), pump-only, multiple daily injections (MDI)+CGM, MDI-only
- Participants
- 168 individuals
- Comparison
- Closed-loop control (CLC) vs sensor-augmented pump (SAP) across baseline device-use subgroups
Methodological detailssubgroup analysis, multicenter, six-month, two- to eight-week run-in phase
- Subgroup analysis
- Multicenter
- Six-month
- Two- to eight-week run-in phase
Primary result
As reported in the abstract
Mean TIR 70-180 mg/dL with CLC, baseline to follow-up, by baseline device-use subgroup
pump+CGM (CLC)
62% to 73%
Pump-only (CLC)
61% to 70%
MDI+CGM (CLC)
54% to 68%
MDI-only (CLC)
61% to 69%
Further findings
| Outcome | P value |
|---|---|
| Time below 70 mg/dL, reduction from baseline by subgroupNo interaction effect detected | P = 0.77 |
Time below 70 mg/dL, reduction from baseline by subgroup
- Reduction in time below 70 mg/dL comparable among the four subgroups
System Usability Questionnaire score by subgroup · 26 weeks
- pump+CGM
- 87.2 ± 12.1
- Pump-only
- 89.4 ± 8.2
- MDI+CGM
- 87.2 ± 9.3
- MDI
- 78.1 ± 15
- Scores high for all subgroups
Baseline device use distribution
- pump+CGM
- 61%
- Pump-only
- 18%
- MDI+CGM
- 10%
- MDI-only
- 11%
Original publication
Outcomes in Pump- and CGM-Baseline Use Subgroups in the International Diabetes Closed-Loop Trial. J Diabetes Sci Technol. Published 26 April 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →